Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

ERT) with Cerezyme(R) (imiglucerase) to the pharmacological chaperone Plicera(TM). Thirty patients were enrolled in this trial, which was designed to demonstrate safety and to evaluate various doses and dose regimens of Plicera. The study subjects on average were on ERT with Cerezyme(R) for ten years prior to entering this study.

Preliminary data are available for the first twenty study subjects. Key findings include the following:

-- Plicera was generally safe and well-tolerated at all doses evaluated

and no serious adverse events have been reported

-- The level of the enzyme deficient in people with Gaucher disease

(GCase) as measured in white blood cells increased in 15 of the 20

patients

-- In the cohort with the highest Plicera exposure, 5 out of 5 patients

responded to Plicera with, on average, a near tripling of their GCase

levels from baseline

-- The 5 patients without a clear increase in GCase levels from baseline

were in either the lowest dose cohort or the cohort dosed least

frequently

-- 16 of 20 patients in this study had at least one copy of the N370S

mutation, the most common mutation known to cause Type 1 Gaucher

disease.

"As the Gaucher program at Amicus advances, it has increasing significance and value for our company. Plicera has the potential to address the needs of the vast majority of people living with Gaucher disease and may offer a new standard of care in the treatment and maintenance of their disease. We expect to move forward aggressively in 2008 with additional studies as we explore the full potential of switching Gaucher patients from Cerezyme(R) to Plicera," said John F. Crowley, Amicus President & CEO.

Amicus expects that the results for all thirty patients enrolled in the first Plicera Phase 2 study to be presented at the ACMG meeting in March.

Pompe Disease:

During the fourth quarte
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... This is a professional and in-depth study on ... Global and China. The report provides a basic overview ... structure. Global market analysis and Chinese domestic market analysis ... and competitive landscape of the market. A comparison between ... The report also focuses on development policies and plans ...
(Date:8/1/2014)... 1. 2014 As one of the 10 ... Annual Meeting & Clinical Lab Expo is the place ... are introduced to the healthcare world. This year, many ... exhibitors will include the latest diagnostic technology in the ... smartphones and biosensors have enabled the development of "labs-on-a-chip" ...
(Date:8/1/2014)... , Aug. 1, 2014 The  PROPEL Center ... number and success rate of early-stage life sciences companies ... it has awarded 15 grants to help ... The MedTech Conference   in Chicago ... conference in North America , bringing ...
(Date:8/1/2014)... 01, 2014 Once a decision has ... This webinar will discuss how to define your tolerance ... speakers Bob Allen, Senior Director of Facilities Integration at ... at Fluor Industrial Services, and special guest Carrier Li, ... at Amgen, as they provide an examination of the ...
Breaking Biology Technology:Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 2Ammonium Bicarbonate Market in Internations & Chinese Regions Research Analysis Now Available at DeepResearchReports.com 3Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 2Lab-on-a-Chip Technology to Be Featured at 2014 AACC Annual Meeting & Clinical Lab Expo 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 2iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 3iBIO Institute's PROPEL Center Awards Grants for AdvaMed 2014 to Early-Stage Life Sciences Companies 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2
... Chinmax Medical Systems Inc., a leading cardiac biomarker distributor ... its lawsuit against Inverness Medical Beijing (IMB), a subsidiary ... the Complaint, Inverness Medical Beijing secretly imported massive quantities ... customers during the period when Chinmax retained the undisputed ...
... April 11, 2011 Leading experts from around the world ... the 6th Canine Vector Borne Disease (CVBD) forum in Nice, ... to animals and humans by these increasingly important diseases. ... and even death in dogs, and many CVBDs represent a ...
... MabVax Therapeutics, Inc., a privately held clinical stage ... antibody based therapies to address the unmet medical need ... the Phase 2 portion of the Small Business Innovation ... under the agency,s Streamlined Non-competing Award Procedures (SNAP). The ...
Cached Biology Technology:Beijing Chaoyang District Court Grants Investigation Letters Against Inverness Medical Beijing, A Subsidiary of Alere Inc. 2Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 2Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 3Veterinarians and Pet Owners Urged to Act Upon Evolving Dangers Posed by CVBDs as New Research Underlines Threats to Animals and Humans 4MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 3
(Date:7/31/2014)... ago, prestin was found to be a key gene responsible ... in the hair cells of the inner ear that contracts ... like an antique phonograph horn, amplify sound waves to make ... published in the advanced online edition of Molecular Biology ... prestin has also independently evolved to play a critical role ...
(Date:7/31/2014)... the largest minority group in the United States, comprising ... are obese and are 1.2 times as likely to ... College of Nursing student researcher Lauren Gerchow, BSN, RN, ... contribute to this problem by compiling a systematic review ... Latina women recently published in Nursing Research . ...
(Date:7/31/2014)... of the roughly 156,000 gas stations across the ... parts of underground gas storage tankscorrosion that could ... a source of drinking water. In recent years, ... rapidly corroding gas storage tank components such as ... use of gasoline-ethanol blends and the presence of ...
Breaking Biology News(10 mins):NYU research looks to combat US Latina immigrant obesity 2NIST corrosion lab tests suggest need for underground gas tank retrofits 2
... Wisconsin research team, led by John W. Lough, Ph.D., professor ... stem cells (ES cells) in animals can be cultivated to ... to replace tissue damaged as a result of a heart ... or diseased cells in adult tissues has caused extraordinary interest ...
... Durham, N.C. ?A new understanding of the causes for symptoms ... 600 African-Americans, has resulted from a study by researchers at ... Their findings may lead to a new, more direct method ... that an inability of red blood cells to relax blood ...
... each year worldwide, causing one million deaths. Around 90% ... children. One of the greatest challenges facing Africa in ... chloroquine (CQ), the cheapest and most widely used antimalarial, ... the first-developed and least expensive alternative to CQ, is ...
Cached Biology News:Stem Cell Research Shows Potential for Replacing Tissue Damaged in Heart Attacks 2Discovery Promises Simpler Therapy for Sickle Cell Disease 2Discovery Promises Simpler Therapy for Sickle Cell Disease 3Reducing malarial transmission in Africa 2
... Thermo has established an expertise in ... both for solid support synthesis and synthesis ... controlled by Mass Spectrometry and analytical HPLC ... provide products that meet the highest quality ...
The Wellwash 4 Mk 2 microplate washer combines flexibility, simplicity and ease of use. This reliable microplate washer meets the exacting standards of today's ELISA assay requirements....
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Many other sizes and ...
Biology Products: